Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hypertension crises and management during radiofrequency ablation of adrenal pheochromocytoma: A case report.
Radiol Case Rep
September 2024
Department of Interventional Radiology, Pardis Noor Medical Imaging and Cancer Center, Tehran, Iran.
This case report describes the radiofrequency (RF) ablation of a pheochromocytoma in a 35-year-old female with multiple endocrine neoplasia (MEN) II syndrome, who previously underwent a right adrenalectomy and thyroidectomy. The patient presented with a new tumor in the left adrenal gland, detected via imaging, without evidence of metastasis. Opting against surgical adrenalectomy due to previous surgeries, she underwent RF ablation after preparatory alpha and beta blockader.
View Article and Find Full Text PDFPD-1 blockader-associated atypical hemophagocytic lymphohistiocytosis: A cautionary case report.
Transfus Apher Sci
April 2023
Blood transfusion department of Yijishan Hospital, The First Affiliated Hospital of Wannan Medical College, Wuhu, 241001, People's Republic of China.
Article Synopsis
- Hemophagocytic lymphohistiocytosis (HLH) is a severe immune disorder with high mortality that's especially concerning for patients receiving immune checkpoint inhibitors, like PD-1 blockers.
- A 36-year-old patient with metastatic angiosarcoma developed HLH after treatment with PD-1 blocker toripalimab and pazopanib, leading to a unique case with no established guidelines for diagnosis or treatment.
- The patient showed rapid improvement after just one therapeutic plasma exchange (TPE) procedure and was discharged after two, suggesting TPE might be a promising treatment option for HLH linked to immunotherapy, though more research is needed.
Mechanisms underlying immune-related adverse events during checkpoint immunotherapy.
Clin Sci (Lond)
May 2022
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Immune checkpoint (IC) proteins are some of the most important factors that tumor cells hijack to escape immune surveillance, and inhibiting ICs to enhance or relieve antitumor immunity has been proven efficient in tumor treatment. Immune checkpoint blockade (ICB) agents such as antibodies blocking programmed death (PD) 1, PD-1 ligand (PD-L) 1, and cytotoxic T lymphocyte-associated antigen (CTLA)-4 have been approved by the U.S.
View Article and Find Full Text PDFNear-Infrared Photoactivatable Semiconducting Polymer Nanoblockaders for Metastasis-Inhibited Combination Cancer Therapy.
Adv Mater
November 2019
School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Drive, Singapore, 637457, Singapore.
Inhibition of protein biosynthesis is a promising strategy to develop new therapeutic modalities for cancers; however, noninvasive precise regulation of this cellular event in living systems has been rarely reported. In this study, a semiconducting polymer nanoblockader (SPN ) is developed that can inhibit intracellular protein synthesis upon near-infrared (NIR) photoactivation to synergize with photodynamic therapy (PDT) for metastasis-inhibited cancer therapy. SPN is self-assembled from an amphiphilic semiconducting polymer which is grafted with poly(ethylene glycol) conjugated with a protein biosynthesis blockader through a singlet oxygen ( O ) cleavable linker.
View Article and Find Full Text PDFThe safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Expert Opin Drug Saf
January 2017
a Medical Oncology , Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia , Perugia , Italy.
Immune checkpoint blockaders (ICBs) act by unbalancing the immune system, thus favoring the development of an immune-mediated antitumor effect. ICBs targeting the programmed cell death receptor-1 (PD-1) have recently been investigated in a number of advanced tumors, including non-small cell lung cancer (NSCLC). Nivolumab, a fully human IgG4 kappa directed against PD-1, has been the first ICB to be approved for second-line treatment of advanced NSCLC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!